Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553160 | 1.00 | PKM (0.46) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL13388412 | 0.91 | RAB9A (0.41) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL13388408 | 0.91 | RAB9A (0.41) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL173452 | 0.87 | PKM (0.58) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL17142326 | 0.87 | PKM (0.58) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL349628 | 0.87 | PKM (0.58) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL837337 | 0.87 | PKM (0.58) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL29362649 | 0.87 | PKM (0.58) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL29478388 | 0.87 | PKM (0.58) | PKMMAPTRAB9ANPC1ALDH1A1 | |
| Fenclonine SCHEMBL252839 | 0.86 | KMT2A (0.39) | PKMSMN1; SMN2GAALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132875-A1 | Single-Molecule Phenotype Analysis | The Trustees of the California State University (US) | 2024-04-25 | — | — | US | disclosed |
| US-20240108690-A1 | COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS | ELI LILLY AND COMPANY | 2024-04-04 | — | — | US | disclosed |
| WO-2024020302-A2 | EXTRACELLULAR CARBOXYLESTERASE 2 (CES2) FOR THE TREATMENT OF METABOLIC DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230399380-A1 | Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins | GRIFOLS DIAGNOSTIC SOLUTIONS INC. | 2023-12-14 | — | — | US | disclosed |
| US-11814679-B2 | Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same | ELI LILLY AND COMPANY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230324389-A1 | COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS | AMUNIX PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230287040-A1 | BARCODED XTEN POLYPEPTIDES AND COMPOSITIONS THEREOF, AND METHODS FOR MAKING AND USING THE SAME | AMUNIX PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230265146-A1 | CYTOKINE CONJUGATES | AMUNIX PHARMACEUTICALS, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-4185705-A1 | COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS | Amunix Pharmaceuticals, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4171609-A1 | CYTOKINE CONJUGATES | Amunix Pharmaceuticals, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2014080350-A1 | IMMUNOMODULATORY PEPTIDES AND METHODS OF USE THEREOF | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014047357-A1 | MODIFIED FC POLYPEPTIDES, FC CONJUGATES, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014014816-A2 | METHODS OF TREATING GLUCOSE METABOLISM DISORDERS | NGM BIOPHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014014819-A2 | METHODS OF TREATING GLUCOSE METABOLISM DISORDERS | NGM BIOPHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2013151627-A1 | METHODS OF TREATING GLUCOSE METABOLISM DISORDERS | NGM BIOPHARMACEUTICALS, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013148117-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING METABOLIC DISORDERS | NGM BIOPHARMACEUTICALS, INC. (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013101645-A1 | COMPOSITIONS AND METHODS FOR REGULATING GLUCOSE METABOLISM | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-07-04 | — | — | WO | disclosed |
| WO-2012148720-A2 | ANTI-MICROBIAL PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2217614-A1 | ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND USES THEREOF | Dynamic Microbials Limited (AU) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009059379-A1 | ANTIMICROBIAL COMPOSITIONS, FORMULATIONS AND USES THEREOF | DYNAMIC MICROBIALS LIMITED (AU) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132875-A1 | Single-Molecule Phenotype Analysis | FBL, SRPRB, PABPC4 | PKM 2976/4885MAPT 4479/4885RAB9A 2855/4885 |
| US-20240108690-A1 | COMPOSITIONS AND METHODS OF USE OF INTERLEUKIN-10 IN COMBINATION WITH IMMUNE CHECK-POINT PATHWAY INHIBITORS | PDCD10, CD274, PDCD1 | PKM 3463/4885MAPT 2204/4885RAB9A 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.